A Phase IIa/b Double-Blind, Randomised, Placebo-Controlled, Linear Trend Design Dose-Ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.

Trial Profile

A Phase IIa/b Double-Blind, Randomised, Placebo-Controlled, Linear Trend Design Dose-Ranging Study to Investigate the Effects of 24 Weeks of Monotherapy With SB-742457 on Cognition in Subjects With Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Feb 2010 Endpoint methodology added.
    • 31 Jul 2008 Results were presented at the 12th International Conference on Alzheimer's Disease and Related Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top